Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab.

Hoyer BF, Mumtaz IM, Loddenkemper K, Bruns A, Sengler C, Hermann KG, Maza S, Keitzer R, Burmester GR, Buttgereit F, Radbruch A, Hiepe F.

Ann Rheum Dis. 2012 Jan;71(1):75-9. doi: 10.1136/ard.2011.153007. Epub 2011 Sep 27.

PMID:
21953334
2.

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.

Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I.

Arthritis Rheum. 2004 Nov;50(11):3580-90.

3.

Two Takayasu arteritis patients successfully treated with rituximab.

Caltran E, Di Colo G, Ghigliotti G, Capecchi R, Catarsi E, Puxeddu I, Migliorini P, Tavoni A.

Clin Rheumatol. 2014 Aug;33(8):1183-4. doi: 10.1007/s10067-014-2506-5. Epub 2014 Jan 31.

PMID:
24478126
4.

Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosus.

Odendahl M, Keitzer R, Wahn U, Hiepe F, Radbruch A, Dörner T, Bunikowski R.

Ann Rheum Dis. 2003 Sep;62(9):851-8.

5.

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.

Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Prak ET, Kimberly R, Zhang Y, Eisenberg R.

Ann Rheum Dis. 2008 Dec;67(12):1724-31. doi: 10.1136/ard.2007.083162. Epub 2008 Feb 4.

PMID:
18250115
6.

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.

Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA.

Arthritis Rheum. 2009 Apr 15;61(4):482-7. doi: 10.1002/art.24341.

7.

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA.

Rheumatology (Oxford). 2005 Dec;44(12):1542-5. Epub 2005 Sep 27.

8.
9.

B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.

Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W.

Ann Rheum Dis. 2008 Jul;67(7):1011-6. Epub 2007 Oct 25.

PMID:
17962238
10.

Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.

Ezeonyeji AN, Isenberg DA.

Rheumatology (Oxford). 2012 Mar;51(3):476-81. doi: 10.1093/rheumatology/ker337. Epub 2011 Nov 16.

11.

Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus.

Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, Lipsky PE, Radbruch A, Dörner T.

J Immunol. 2000 Nov 15;165(10):5970-9.

12.

Peripheral CD24hi CD27+ CD19+ B cells subset as a potential biomarker in naïve systemic lupus erythematosus.

Jin L, Weiqian C, Lihuan Y.

Int J Rheum Dis. 2013 Dec;16(6):698-708. doi: 10.1111/1756-185X.12229. Epub 2013 Nov 28.

PMID:
24286662
13.

B cell homeostasis is disturbed by immunosuppressive therapies in patients with ANCA-associated vasculitides.

Thiel J, Salzer U, Hässler F, Effelsberg NM, Hentze C, Sic H, Bartsch M, Miehle N, Peter HH, Warnatz K, Schlesier M, Voll RE, Venhoff N.

Autoimmunity. 2013 Nov;46(7):429-38. doi: 10.3109/08916934.2013.798652. Epub 2013 Jun 6.

PMID:
23742274
14.

Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.

Kötter I, Henes JC, Wagner AD, Loock J, Gross WL.

Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S114-29. Epub 2012 May 11. Review.

PMID:
22640655
15.

HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus.

Jacobi AM, Mei H, Hoyer BF, Mumtaz IM, Thiele K, Radbruch A, Burmester GR, Hiepe F, Dörner T.

Ann Rheum Dis. 2010 Jan;69(1):305-8. doi: 10.1136/ard.2008.096495. Epub .

PMID:
19196727
16.

[Progress in B-cell targeting therapy for the treatment of systemic lupus erythematosus].

Tanaka Y.

J UOEH. 2011 Jun 1;33(2):173-81. Review. Japanese.

PMID:
21702122
17.

Circulating B lymphocytes producing autoantibodies to endothelial cells play a role in the pathogenesis of Takayasu arteritis.

Wang H, Ma J, Wu Q, Luo X, Chen Z, Kou L.

J Vasc Surg. 2011 Jan;53(1):174-80. doi: 10.1016/j.jvs.2010.06.173. Epub 2010 Sep 15.

18.

[The role of rituximab in the treatment of ANCA-associated systemic vasculitis].

Roccatello D, Vangelista A, Pani A.

G Ital Nefrol. 2011 Sep-Oct;28(5):474-88. Review. Italian.

PMID:
22028261
19.

B-cell-targeted therapy for systemic lupus erythematosus.

Sabahi R, Anolik JH.

Drugs. 2006;66(15):1933-48.

PMID:
17100405
20.
Items per page

Supplemental Content

Write to the Help Desk